Home » Stocks » MRVI

Maravai LifeSciences Holdings, Inc. (MRVI)

Stock Price: $37.15 USD 1.57 (4.41%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $37.95 +0.80 (2.15%) May 7, 5:57 PM
Market Cap 384.54M
Revenue (ttm) 284.10M
Net Income (ttm) 88.97M
Shares Out 10.35M
EPS (ttm) 2.36
PE Ratio 15.74
Forward PE 41.84
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $37.15
Previous Close $35.58
Change ($) 1.57
Change (%) 4.41%
Day's Open 36.12
Day's Range 35.47 - 37.64
Day's Volume 738,739
52-Week Range 23.62 - 40.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

Other stocks mentioned: NSTG, SDC, SWAV, TGTX
23 hours ago - Zacks Investment Research

SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to part...

2 days ago - GlobeNewsWire

Maravai LifeSciences Holdings, Inc. (MRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

4 days ago - Zacks Investment Research

Stock Market Shrugs Off J&J News; Tesla, New IPO Roblox, Vaccine Play Maravai Flash Buy Signals

YouTube video

Stock market rally shrugs off J&J news; Tesla, new IPO Roblox, vaccine play Maravai flash buy signals. Investor's Business Daily has been helping people invest smarter results by providing exclusive sto...

Other stocks mentioned: RBLX, TSLA
3 weeks ago - Investors Business Daily

SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to...

3 weeks ago - GlobeNewsWire

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators,...

3 weeks ago - GlobeNewsWire

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators,...

1 month ago - GlobeNewsWire

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators,...

1 month ago - GlobeNewsWire

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai or the Company) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biot...

1 month ago - GlobeNewsWire

New integrated offering will help to meet expected increases in global demand by simplifying and accelerating production of GMP-grade mRNA product for downstream vaccine and therapeutic manufacturing Ne...

1 month ago - GlobeNewsWire

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators,...

2 months ago - GlobeNewsWire

SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to pa...

2 months ago - GlobeNewsWire

Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics

2 months ago - GlobeNewsWire

SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences , Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to...

3 months ago - GlobeNewsWire

Stocks Rebound; Qualcomm, Maravai, One Medical Clear Buy Points

YouTube video

Stocks rebound, Qualcomm, Maravai, One Medical clear buy points. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market...

Other stocks mentioned: ONEM, QCOM
3 months ago - Investors Business Daily

SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today ann...

5 months ago - GlobeNewsWire

Maravai LifeSciences has received a welcome public debut. The company provides a crucial role in drug development and in fact even in the Pfizer/BioNTech vaccine.

5 months ago - Seeking Alpha

SAN DIEGO, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech inno...

5 months ago - GlobeNewsWire

Maravai Life Sciences Holdings (NASDAQ:MRVI) will hit the public markets with perfect timing as it sees its mRNA product used by COVID-19 vaccine makers. The Offering: Maravai Life Sciences plans on sel...

5 months ago - Benzinga

About MRVI

Maravai LifeSciences is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. Our more than 5,000 customers as of September 30, 2020 include the top 20 global biopharmaceutical companies ranked by research and development expenditures according to industry consultants, and many other emerging biopharmaceutical and life sciences research companies, as well as leading academic research institutes and in vitro diagnostics companie... [Read more...]

Industry
Biotechnology
IPO Date
Nov 20, 2020
CEO
Carl W. Hull
Employees
410
Stock Exchange
NASDAQ
Ticker Symbol
MRVI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for MRVI stock is "Strong Buy." The 12-month stock price forecast is 48.78, which is an increase of 31.31% from the latest price.

Price Target
$48.78
(31.31% upside)
Analyst Consensus: Strong Buy